Cancer (Neoplastic Diseases - Malignant)
| Author | David A. Morton III |
| Pages | 437-826 |
13-1
CHAPTER 13
Neoplastic Diseases – Malignant
Contents
Part I – Adults
§13.00 Cancer (Neoplastic Diseases, Malignant)
§13.01 Category of Impairments, Cancer (Malignant Neoplastic Diseases)
§13.02 Soft Tissue Cancers of the Head and Neck
§13.03 Skin
§13.04 Soft Tissue Sarcoma
§13.05 Lymphoma
§13.06 Leukemia
§13.07 Multiple Myeloma
§13.08 Salivary Glands
§13.09 Thyroid Gland
§13.10 Breast
§13.11 Skeletal System
§13.12 Maxilla, Orbit, or Temporal Fossa
§13.13 Nervous System
§13.14 Lungs
§13.15 Pleura or Mediastinum
§13.16 Esophagus or Stomach
§13.17 Small Intestine
§13.18 Large Intestine
§13.19 Liver or Gallbladder
§13.20 Pancreas
§13.21 Kidneys, Adrenal Glands, or Ureters
§13.22 Urinary Bladder
§13.23 Cancers of the Female Genital Tract
§13.24 Prostate Gland
§13.25 Testicles
§13.26 Penis
§13.27 Primary Site Unknown—Metastatic Carcinoma or Sarcoma
§13.28 Cancer Treated with Transplants
§13.29 Malignant Melanoma
MEDICAL ISSUES IN SOCIAL SECURITY DISABILITY 13-2
Part II – Children
§113.00 Cancer (Neoplastic Diseases, Malignant)
§113.01 Category of Impairments, Cancer (Malignant Neoplastic Diseases)
§113.02 (Reserved)
§113.03 Malignant Solid Tumors
§113.04 (Reserved)
§113.05 Lymphoma
§113.06 Leukemia
§113.07 (Reserved)
§113.08 (Reserved)
§113.09 Thyroid Gland
§113.10 (Reserved)
§113.11 (Reserved)
§113.12 Retinoblastoma
§113.13 Nervous System
§113.14-28 (Reserved)
§113.29 Malignant Melanoma
Part III – Forms
§13.02F Soft Tissue Tumors of Head and Neck
§13.03F Skin Cancer
§13.04F Soft Tissue Sarcomas
§13.05F Lymphoma
§13.06F Leukemia
§13.07F Multiple Myeloma
§13.08F Salivary Glands Cancer
§13.09F Thyroid Cancer
§13.10F Breast Cancer
§13.11F Skeletal System Cancer
§13.12F Cancer of Maxilla, Orbin, or Temporal Fossa
§13.13F Nervous System Cancer
§113.03F Malignant Solid Tumors in Children
§113.12F Retinoblastoma in Children
§13.13F Nervous System Cancer
§13.14F Lung Cancer
§13.15F Cancer of Pleura or Mediastinum
§13.16F Cancer of Stomach or Esophagus
§13.17F Cancer of Small Intestine
§13.18F Cancer of Large Intestine
§13.19F Cancer of Liver, Gallbladder, or Bile Ducts
§13.20F Cancer of Pancreas
§13.21F Carcinoma of Kidneys, Adrenal Glands, Ureters
§13.22F Carcinoma of Urinary Bladder
§13.23F Cancer of Female Genital Tract
§13.24F Carcinoma of Prostate
§13.25F Testicular Cancer
§13.26F Cancer of Penis
§13.27F Cancer With Unknown Primary
§113.03F Malignant Solid Tumors in Children
§113.12F Retinoblastoma in Children
13-3 NEOPLASTIC DISEASES – MALIGNANT §13.00
Form Reference:
See Forms 13.02, 13.03, 13.04, 13.05, 13.06, 13.07,
13.08, 13.09, 13.10, 13.11, 13.12, 13.13, 13.14, 13.15,
13.16, 13.17, 13.18, 13.19, 13.20, 13.21, 13.22, 13.23,
13.24, 13.25, 13.26, 13.27, 113.03, 113.12 to solicit treat-
ing source medical information relevant to the above
adult and corresponding child listings.
[Note: There is no Form 13.28 with listing 13.28, dealing
with cancer treated by bone marrow or stem cell trans-
plantation. In these cases, use Form 7.17.]
Part I – Adults
§13.00 Cancer (Malignant
Neoplastic Diseases)
[The applicable Listing of Impairments introduces
each chapter and is typeset in Helvetica. Author comments
follow each Listing subsection and are typeset in Times.]
SSA Listing of Impairments
A. What impairments do these listings cover? We use
these listings to evaluate all cancers (malignant neoplastic
diseases) except certain cancers associated with human
criteria in 14.11B to evaluate primary central nervous
lymphoma, and 14.11E to evaluate pulmonary Kaposi
Hodgkin lymphoma or non-pulmonary Kaposi sarcoma,
under this body system or under 14.11F-I in the immun
system disorders body system.
B. What do we consider when we evaluate malignant
neoplastic diseases under these listings? We consider
factors such as the:
1. Origin of the malignancy.
2. Extent of involvement.
3. Duration, frequency, and response to anticancer
therapy.
C. How do we apply these listings? We apply the crite-
D. What evidence do we need?
extent, and site of the primary, recurrent, or metastatic
will use evidence documenting the site(s) of metastasis
to evaluate the impairment under 13.27.
2. For operative procedures, including a biopsy or a
needle aspiration, we generally need a copy of both the:
a. Operative note.
b. Pathology report.
3. When we cannot get these documents, we will
accept the summary of hospitalization(s) or other med-
ical reports. This evidence should include details of the
-
4. In some situations we may also need evidence about
recurrence, persistence, or progression of the cancer,
(See 13.00G.)
E. When do we need longitudinal evidence?
1. Tumors with distant metastases. We generally
do not need longitudinal evidence for cancer that has
metastasized beyond the regional lymph nodes because
these cancers usually meet the requirements of a listing.
Exceptions are for cancers with distant metastases that
are expected to respond to anticancer therapy.
For these exceptions, we usually need a longitudi-
nal record of 3 months after therapy starts to determine
and is likely to persist.
2. Other Cancers. When there are no distant metasta-
ses, many of the listings require that we consider your
response to initial anticancer therapy; that is, the initial
planned treatment regimen. This therapy may consist of
a single modality or a combination of modalities; that is,
multimodal therapy (see 13.00I3).
3. Types of treatment.
a. Whenever the initial planned therapy is a single
modality, enough time must pass to allow a deter-
mination about whether the therapy will achieve its
often happen within 6 months after the treatment
starts, and there will often be a change in the treatment
To continue reading
Request your trial